Trial Information
Expression of Met Receptor Fragments in Non Small Cell Lung Cancer
Inclusion Criteria:
- Patients with non small cell lung cancer (NSCLC)
- Patients candidate for bronchial biopsies on Centre Oscar Lambret (metastatic stage)
or candidate for thoracic surgery on CHRU de Lille (localized stage)
- Chemo-naive for metastatic NSCLC
- Patients with or without induction chemotherapy for localized NSCLC
- Male or female subjects ≥ 18 years of age
- Ability to understand and willingness to sign a written Informed Consent
Exclusion Criteria:
- Non malignant tumors
- Small-cell malignancies
- Secondary malignant lesions
- Reversal surgery
- Pregnant or breastfeeding women
- Patient under guardianship
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Outcome Measure:
Evaluate the expression of Met C-terminal active fragments in NSCLC
Outcome Description:
Expression and localization of Met C-terminal active fragments in NSCLC(Western Blot and immunohistochemistry)
Outcome Time Frame:
baseline
Safety Issue:
No
Authority:
France: Committee for the Protection of Personnes
Study ID:
MetLung - 1204
NCT ID:
NCT01647867
Start Date:
July 2012
Completion Date:
July 2013
Related Keywords:
- Non Small Cell Lung Cancer
- non small cell lung cancer
- Met fragments
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms